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Abstract
Since the term RNA interference (RNAi) was coined in 1998, much knowledge about RNAi has accumulated. Presently,
RNAi is known as a power tool for studying gene function as well as a potential therapeutic molecular technique for a wide
range of disorders. This review discusses potential problem areas such as off-target effects, in vivo delivery and RNAi
saturation, and also indicates solutions including the current stage of RNAi therapeutics.
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1. Introduction to RNA Interference
RNA interference (RNAi) is a specific mechanism for
controlling down-regulation of gene expression. It is evo-
lutionally  conserved  in  plants,  Caenorhabditis  elegans,
Drosophila melanogaster, non-mammalian vertebrates and
mammals (Bosher and Labouesse, 2000; Naqvi, et al., 2009;
Poethig  et  al.,  2006;  Ramadan  et  al.,  2007).  The  RNAi
process is initiated by short double-stranded RNAs (dsRNAs)
that lead to the sequence-specific inhibition of their homo-
logous genes (Figure 1). These short dsRNAs (21-25 nucleo-
tides in length) are normally produced in cells from cleavage
of longer dsRNA precursors by the ribonuclease III (RNase
III) family member Dicer (Zhang et al., 2004) and incorpor-
ated into a multi-component nuclease complex known as the
RNA-induced silencing complexes (RISC), which has the
splicing  protein  Argonaute-2  (Ago-2)  (Hammond  et  al.,
2000). Then, the single stranded RNA derived from the short
dsRNA  acts  as  a  guide  sequence  (the  antisense  strand)
directing the complex to the specific target mRNA by inter-
molecular base pairing, where a RISC-associated endoribo-
nuclease silences the target mRNA (Bartel, 2004; Khvorova
et al., 2003; Schwarz et al., 2003)
In eukaryotic cells, two major types of short dsRNAs
are present in the RNAi pathway, namely small interfering
RNAs (siRNAs) and microRNAs (miRNAs). In more detail,
siRNAs have a characteristic two nucleotides 3 overhang,
which  are  processed  from  larger  dsRNAs  by  Dicer.  The
siRNAs are incorporated into RISC and the sense strand of
the siRNA is removed in an ATP-dependent manner. The
antisense strand of the siRNA perfectly pairs with its target
mRNA, where RISC mediates endonucleolytic cleavage and
subsequent degradation of the target RNA (Elbashir et al.,
2001; Fire et al., 1998; Parrish et al., 2000) (Figure 1). On the
other hand, miRNAs are initially processed from long pri-
mary transcripts (pri-miRNA) within the nucleus into 60-70
base-paired hairpins known as precursor miRNAs (pre-
miRNAs) by the microprocessor complex, which consists of
Drosha-DGCR8 (Han et al., 2004; Lee et al., 2003). Following
processing  by  Drosha,  the  pre-miRNA  is  exported  to  the
cytoplasm  by  the  Ran-GTP  dependent  cargo  transporter
Exportin-5 (Bollman, et al., 2003). In the cytoplasm the pre-
miRNA is processed by Dicer into the mature miRNA, which
is incorporated into RISC. In much the same way that siRNA
functions, the mature miRNA guides the complex to the target
mRNA for translational repression or message degradation
(Beverley, 2003). Notably, typical miRNAs are not perfectly
matched to their mRNA targets and exert silencing through
translational suppression (Ambros et al., 2003; Nelson et al.,
2004) (Figure 1).
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Currently,  RNAi  has  become  a  powerful  tool  for
reverse functional genomics. In addition, it has been employed
as a potential molecular therapeutic method for combating
a wide range of disorders including autoimmune diseases,
metabolic disorders, viral infections, neurological diseases
and cancer in many studies using mammalian tissue culture
system or the mouse model. For example, the expression of
mutant p53 or RAS genes that are observed in most tumour
cells was specifically silenced in SW480 human colon cancer
cells  by  siRNAs  without  affecting  the  wild  type  genes
(Kawasaki and Taira, 2003). Target of siRNAs to human
telomerase RNA inhibited telomerase activity in variety of
human  cancer  cell  lines  (Kosciolek  et  al.,  2003).  Several
pioneering studies have demonstrated great possibilities for
using siRNAs for treating serious viral diseases that caused
by  HIV  and  HCV  (Jakobsen  et  al.,  2009;  Lee  et  al.,  2002;
Wilson et al., 2003).
In  addition,  recent  studies  indicated  that  some
miRNAs are linked to several human diseases including viral
and metabolic diseases. Therefore, inhibition or interference
of miRNAs function could potentially be a new therapeutic
approach (McBride et al., 2008).
Despite the numerous successful studies of RNAi on
inhibition of specific genes in the mammalian tissue culture
system, inefficient delivery system, poor intracellular uptake
and  off-target  effects  have  impeded  RNAi  therapeutics.
Albeit clinical trials with RNAi have now begun, challenges
such as off-target effects, toxicity and the need for safe and
efficient delivery methods have to be overcome before using
RNAi for gene therapy.
2. RNAi and Gene Therapy
In medical sciences, the term gene therapy has been
indicated for more than 10 years. Several innovative therapeu-
tic modalities have been investigated including numerous
potent drugs such as anti-sense, ribozymes and the use of
regulatory  elements  for  reversing  malignant  phenotypes
(Pan et al., 2009; Quon and Kassner, 2009; Schmidt, 2009).
Clinical studies of current gene therapy have experienced
significant obstacles such as the unexpected frequency of
major side effects, inefficient gene delivery method and the
high cost of the therapy (Aagaard and Rossi, 2007; Li and
Shen, 2009).
For RNAi, the specificity of mechanism, large scale
silencing  and  a  natural  defence  mechanism  are  attractive
criteria for being a good molecular therapeutic method
(Aagaard and Rossi, 2007; Ebbesen et al., 2008; Inoue et al.,
 
Figure 1. RNAi mechanism. The left hand side demonstrates of the mammalian miRNA pathway. The right hand side shows the pathway
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2006). The concept of successful RNAi therapeutics is based
on 3 main conditions: (i) lack of toxicity, (ii) specificity and
(iii) efficacy (usually measured as half-maximal inhibition
levels or IC50 values) in vitro and in vivo (Ichim et al., 2004;
Takeshita and Ochiya, 2006; Vorhies and Nemunaitis, 2007).
The major challenge in RNAi gene therapy is the delivery of
siRNAs or miRNAs to the desired cell type, tissue or organ.
2.1 Delivery of RNAi
Most of reviews classify delivery of RNAi based on
the delivery systems: viral and non-viral methods. As these
two  systems  are  selectively  used  for  molecules  that  are
carried to trigger RNAi pathways, this review article describes
two basic strategies used to activate RNAi pathways: (i) a
RNA  based - approach  by  delivery  of  synthetic  21  base
siRNA duplex (Figure 1) and (ii) a DNA-based method in
which  the  active  siRNAs  are  generated  from  longer  RNA
hairpin transcripts that are transported to the cytoplasm via
the miRNA machinery and are processed into active siRNAs
by Dicer (Figure 2).
1) Delivery of siRNA duplexes
Cellular  delivery  of  synthetic  siRNA  duplexes  is
usually  achieved  by  cationic  liposome - based  strategies.
Liposome and synthetic siRNAs are complexed in vitro and
taken up by cells via the endosomal pathway, Then, siRNAs
are released into the cytoplasm where they associate with
RISC (Sioud and Sorensen, 2003). Although this approach
is considered to be passive and its lack the ability to target
specific cells or tissue, it provides a safer delivery compared
to intravenous injection or local administration of naked
siRNA. Naked siRNA delivery for therapeutic purposes is
ineffective due to the instability of siRNA, low bioactivity
and high dosage requirement of siRNA. Moreover, naked
siRNA is incapable of crossing the blood-brain barrier.
The transient transfection of liposome-siRNA com-
plex typically shows effects of gene silencing for 3-5 days
in culture cells whereas the effects could be sustained for
several weeks in non-dividing cells (Omi et al., 2004; Song
et al., 2003). As mentioned above, the disadvantage of this
approach  in  vivo  is  the  rapid  liver  clearance  and  lack  of
target specificity (Jones, 2009; Sioud and Sorensen, 2003). To
improve  in  vivo  stability  of  siRNA  duplex,  backbone  of
siRNA is chemically modified and linked to molecules such
as 2F, 2O-Me and 2H. As a result, such molecules show an
improved stability of siRNAs in serum and do not reduce
RNAi efficiency (Shiraishi et al., 2008; Watts et al., 2007).
Alternatively, in vivo delivery methods for siRNAs include
the use of Atelocollagen (Minakuchi et al., 2004), conjuga-
tion of cholesterol to the siRNA sense strand (Han et al.,
2008),  binding  of  antibody-protamine  fusion  to  siRNAs
(Song et al., 2005), aptamer-siRNA conjugates (McNamara
et al., 2006), and cyclodextrin nanoparticles (Hu-Lieskovan
et al., 2005). The approaches target siRNAs to specific tissue
or cell type and could potentially be translated into clinical
studies.
2) Delivery of short hairpin RNAs (shRNAs)
Since production of synthetic siRNA duplex is costly,
DNA-based expression cassettes are alternatively used to
generate  the  functional  siRNA  in  cells.  Like  siRNA  duplex
Figure 2. Schematic diagram indicates induction of RNAi pathway by DNA based expression vectors designed to express short hairpin
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delivery, DNA-based shRNA plasmids do not readily cross
the  cellular  membrane  because  of  their  negative  charge.
Therefore, they require facilitating carriers such as cationic
liposome, Atelocollagen or viral vectors. Presently, there are
a number of viral vectors available. Each type of viral vector
has specific characteristics that need to be determined for
the specific therapeutic target. The adenovirus and adeno-
associated virus (AAV) derived vectors provide an efficient
delivery vehicle for transient shRNA expression (Gao et al.,
2004). Particularly, the Ad-gutless vector is used for liver
directed systemic delivery with prolonged silencing effects
(Hosono et al., 2004) while a conditionally replicating aden-
ovirus (CRAd) is designed to replicate and kill tumour cells
specifically (Carette et al., 2004). Retroviruses on the other
hand provide a major advantage to incorporate the trans-
genic siRNAs into the host cell genome. Potential retroviral
vectors  used  for  RNAi  therapeutics  are  Moloney  murine
leukaemia virus (Mo-MuLV) and lentivirus such as human
immunodeficiency virus (HIV), feline immunodeficiency virus
(FIV) or equine infectious anaemia virus (EIAV) (Poeschla,
2003). Several studies indicated that the Mo-MuLV and
lentivirus based-vectors are efficient delivery system, which
can  significantly  silence  expression  of  target  genes  in  a
specific manner (Amendola et al., 2009; Frka et al., 2009;
Sun and Rossi, 2009; Ye et al., 2009).
Despite the high transfection efficiency demonstrated
by viral systems, this approach raises safety concerns for
human use because of the associated oncogenic potential
and immunological complications.
Additional examples of recent RNAi mediated ap-
proaches against viral infection, cancer and metabolic dis-
eases are summarized in  Table 1.
2.2 Off-target effects
Despite  the  specific  mechanism  of  RNAi,  some
studies reported that siRNAs can have off-target effects. For
example, strings of dsRNAs (pri-siRNAs/pri-miRNAs) can
trigger non-specific cellular innate immune response such as
the  interferon  response.  Cullen  (2006)  demonstrated  that
longer dsRNAs (more than 30 nucleotides in length) could
induce interferon response by binding to double-stranded-
RNA-activated protein kinase (PKR), 2, 5-oligoadenylate
synthetase-RNase  L  system  or  several  Toll-like  receptors
(TLRs) (Hornung et al., 2005). Therefore, the use of longer
dsRNAs raises concern over the risk of increased immune
stimulation. Analysis of interferon response can be done by
checking the level of expression of an interferon-response
gene such as oligoadenylate synthase-1 (OAS1) (Bridge et
al., 2003; Fish and Kruithof, 2004). In addition, saturation
of the RNAi machinery due to high concentration of shRNA
transfection is reported to cause toxic non-specific effects.
Competition assays showed that over-expression of shRNA
inhibited miRNA function and saturated the Exportin 5 path-
way.  Therefore,  it  is  important  to  transfect  the  minimum
amount of the siRNA duplex to eliminate the off-target effects
(Cullen, 2006).
3. Clinical Trials for RNAi Therapies
The process of new drug development begins with
extensive pre-clinical studies, which involve in vitro and in
vivo experiments for obtaining pharmacokinetic information
including efficacy and toxicity of the new drug. Pre-clinical
studies of RNAi therapeutics have been widely conducted
against cancer using the mouse model. For example, siRNAs
were used to silence the colorectal cancer-associated gene
beta-catenin, the oncogene H-ras to inhibit tumour growth of
human ovarian cancer, the oncogenic K-ras to inhibit cancer
cells (Brummelkamp et al., 2002; Liu et al., 2007). Results
from  pre-clinical  studies  showed  that  the  siRNAs  were
sufficiently  selective  as  they  only  silenced  expression  of
tumour genes. The results therefore hold promise for further
RNAi therapeutic development.
According to the U.S. National Institutes of Health
(NIH), clinical trials for new drugs can be classified into five
types  based  on  purpose  of  the  trials:  prevention  trials,
screening trials, diagnosis trials, treatment trials and quality
of life trials (The US National Institutes of Health, 2007). They
are conducted following four phases. Phase I trials treat a
small group of people (20-80) for determining a safe dosage
range and identifying side effects. Phase II trials treat a larger
group of people (100-300) for evaluating efficacy and safety.
Phase III trials study a large group of people (1,000-3,000) to
verify the effectiveness of the drug and compare its effects
with current conventional drugs. Phase IV trials consist of
post-approval studies involving safety surveillance such as
risk-benefit  analysis  and  optimal  usage  (National  Cancer
Institute). The process of new drug development will nor-
mally  proceed  through  all  four  phases  over  many  years.
Clinical  trials  for  RNAi  therapies  have  already  begun  and
they belong to the category of treatment trials.
The  first  application  of  RNAi  therapy  is  for  age-
related macular degeneration (AMD) using siRNAs to inhibit
the vascular endothelial growth factor (VEGF) pathway that
causes abnormal growth of blood vessels behind the retina.
This treatment is designed to be administered directly to the
eye  (Takeshita  and  Ochiya,  2006).  In  addition,  the  RNAi
therapies have been extended to investigate infectious dis-
ease from viruses such as hepatitis C (HCV), HIV and Rous
sarcoma virus (RSV). Examples of current trials for RNAi
therapy is summarised in Table 2.
Subsequently, the results of these trails will address
whether RNAi therapeutics cause unpredictable side effects.
4. Conclusion
The RNAi pathway has emerged as a powerful tool
for the study of gene function as well as a new promising
therapeutic approach. Despite challenges such as off-target
effects, toxicity and the need for safe delivery methods, RNAi
therapeutics appears to hold promise in the treatment of dis-297 N. Thienprasert / Songklanakarin J. Sci. Technol. 34 (3), 293-301, 2012
ease along with more conventional approaches.
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